How to buy Galapagos stock

Galapagos NV is a biotechnology business based in the US. Galapagos shares (GLPG) are listed on the NASDAQ and all prices are listed in US Dollars. Galapagos employs 1,489 staff and has a trailing 12-month revenue of around 0.00.

Galapagos share price

Use our graph to track the performance of GLPG stocks over time.

Galapagos shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$74.51 - $233.14
50-day moving average	$79.73
200-day moving average	$101.90
Wall St. target price	$94.35
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.69

Buy Galapagos shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Galapagos stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Galapagos NV by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galapagos financials

Revenue TTM	$530.3 million
Gross profit TTM	$6.6 million
Return on assets TTM	-1.89%
Return on equity TTM	-11.22%
Profit margin	-57.6%
Book value	$40.82
Market capitalisation	$5.2 billion

TTM: trailing 12 months

Shorting Galapagos shares

There are currently 1.1 million Galapagos shares held short by investors – that's known as Galapagos's "short interest". This figure is 0.7% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Galapagos shares can be evaluated.

Galapagos's "short interest ratio" (SIR)

Galapagos's "short interest ratio" (SIR) is the quantity of Galapagos shares currently shorted divided by the average quantity of Galapagos shares traded daily (recently around 285292.67676768). Galapagos's SIR currently stands at 3.96. In other words for every 100,000 Galapagos shares traded daily on the market, roughly 3960 shares are currently held short.

However Galapagos's short interest can also be evaluated against the total number of Galapagos shares, or, against the total number of tradable Galapagos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galapagos's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Galapagos shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Galapagos shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Galapagos.

Find out more about how you can short Galapagos stock.

Galapagos share dividends

We're not expecting Galapagos to pay a dividend over the next 12 months.

Galapagos share price volatility

Over the last 12 months, Galapagos's shares have ranged in value from as little as $74.51 up to $233.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galapagos's is 0.3134. This would suggest that Galapagos's shares are less volatile than average (for this exchange).

Galapagos overview

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc. ; AbbVie S. à r.

Frequently asked questions

• What percentage of Galapagos is owned by institutions?

  Currently 8.611% of Galapagos shares are held by institutions.

• How many people work for Galapagos?

  Latest data suggests 1,489 work at Galapagos.

• When does the fiscal year end for Galapagos?

  Galapagos's fiscal year ends in December.

• Where is Galapagos based?

  Galapagos's address is: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800

• What is Galapagos's ISIN number?

  Galapagos's international securities identification number is: US36315X1019

• What is Galapagos's CUSIP number?

  Galapagos's Committee on Uniform Securities Identification Procedures number is: 36315X101